Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1605, 2007-01, pp. : 19-19
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Pioglitazone, rosiglitazone face up to MI, HF risk analyses
Reactions Weekly, Vol. 1, Iss. 1170, 2007-01 ,pp. :
Access to resources
Recommend
Rosiglitazone and MI risk - will we ever know the answer?
Reactions Weekly, Vol. 1, Iss. 1158, 2007-01 ,pp. :
Pioglitazone is a Valid Alternative to Rosiglitazone
American Journal of Cardiovascular Drugs, Vol. 11, Iss. 6, 2011-12 ,pp. :
Rosiglitazone and MI risk - will we ever know the answer?
Inpharma, Vol. 1, Iss. 1594, 2007-01 ,pp. :
Lower stroke and MI risk with pioglitazone in T2DM
Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. :